Iron: A New Target for Pharmacological Intervention in Neurodegenerative Diseases

Seminars in Pediatric Neurology

Volumn 13, Issue 3, 2006, Pages 186-197

  Whitnall, Megan ^a   Richardson, Des R ^a  

^a UNIVERSITY OF SYDNEY   (Australia)

Author keywords

chelators; Friedreich's ataxia; iron; neurodegeneration; oxidative stress; PIH

Indexed keywords

2 PYRIDYLCARBOXALDEHYDE 2 THIOPHENECARBOXYLHYDRAZONE; 2 PYRIDYLCARBOXALDEHYDE 3 BROMOBENZOYLHYDRAZONE; 2 PYRIDYLCARBOXALDEHYDE ISONICOTINOYLHYDRAZONE; CLIOQUINOL; DEFERIPRONE; DEFEROXAMINE; DIACYLHYDRAZINE ISONICOTINOYLPICOLINOYLHYDRAZINE; HYDRAZONE DERIVATIVE; IRON; IRON CHELATING AGENT; PYRIDOXAL ISONICOTINOYLHYDRAZONE; QUINOLINOL DERIVATIVE; UNCLASSIFIED DRUG;

ALZHEIMER DISEASE; DEGENERATIVE DISEASE; DRUG ACTIVITY; FRIEDREICH ATAXIA; HUMAN; HUNTINGTON CHOREA; IRON METABOLISM; MYELOOPTIC NEUROPATHY; NEUROTOXICITY; NONHUMAN; PARKINSON DISEASE; REVIEW;

ANIMALS; HUMANS; IRON; IRON CHELATING AGENTS; IRON METABOLISM DISORDERS; NEURODEGENERATIVE DISEASES;

EID: 33750716051     PISSN: 10719091     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.spen.2006.08.008     Document Type: Review

References (138)

1. Ponka P. Hereditary causes of disturbed iron homeostasis in the central nervous system. Ann N Y Acad Sci 1012 (2004) 267-281
2. Burdo J.R., and Connor J.R. Brain iron uptake and homeostatic mechanisms: An overview. Biometals 16 (2003) 63-75
3. Harley A., Cooper J.M., and Schapira A.H. Iron induced oxidative stress and mitochondrial dysfunction: Relevance to Parkinson's disease. Brain Res 627 (1993) 349-353
4. Jellinger K.A. The role of iron in neurodegeneration: Prospects for pharmacotherapy of Parkinson's disease. Drugs Aging 14 (1999) 115-140
5. Shoham S., and Youdim M.B. Iron involvement in neural damage and microgliosis in models of neurodegenerative diseases. Cell Mol Biol 46 (2000) 743-760
6. Burdo J.R., and Connor J.R. Iron Transport in the Central Nervous System. Molecular and Cellular Iron Transport (2002), Dekker, New York, NY 487-508
7. Zecca L., Youdim M.B., Riederer P., et al. Iron, brain ageing and neurodegenerative disorders. Nat Rev Neurosci 5 (2004) 863-873
8. Gaeta A., and Hider R.C. The crucial role of metal ions in neurodegeneration: The basis for a promising therapeutic strategy. Br J Pharmacol 146 (2005) 1041-1059
9. Gakh O., Park S., Liu G., et al. Mitochondrial iron detoxification is a primary function of frataxin that limits oxidative damage and preserves cell longevity. Hum Mol Genet 15 (2006) 467-479
10. Richardson D.R., and Ponka P. The molecular mechanisms of the metabolism and transport of iron in normal and neoplastic cells. Biochim Biophys Acta 1331 (1997) 1-40
11. Ponka P., Beaumont C., and Richardson D.R. Function and regulation of transferrin and ferritin. Semin Hematol 35 (1998) 35-54
12. Morgan E. Transferrin biochemistry, physiology, and clinical significance. Mol Aspects Med 4 (1981) 1-123
13. Fleming M.D., Trenor III C.C., Su M.A., et al. Microcytic anaemia mice have a mutation in Nramp2, a candidate iron transporter gene. Nat Genet 16 (1997) 383-386
14. Richardson D.R., and Baker E. Two saturable mechanisms of iron uptake from transferrin in human melanoma cells: The effect of transferrin concentration, chelators, and metabolic probes on transferrin and iron uptake. J Cell Physiol 161 (1994) 160-168
15. Taylor E.M., and Morgan E.H. Developmental changes in transferrin and iron uptake by the brain in the rat. Brain Res Dev Brain Res 55 (1990) 35-42
16. Roberts R.L., Fine R.E., and Sandra A. Receptor-mediated endocytosis of transferrin at the blood-brain barrier. J Cell Sci 104 (1993) 521-532
17. Rothenberger S., Food M.R., Gabathuler R., et al. Coincident expression and distribution of melanotransferrin and transferrin receptor in human brain capillary endothelium. Brain Res 712 (1996) 117-121
18. Demeule M., Poirier J., Jodoin J., et al. High transcytosis of melanotransferrin (P97) across the blood-brain barrier. J Neurochem 803 (2002) 924-933
19. Sekyere E.O., and Richardson D.R. The membrane-bound transferrin homologue melanotransferrin: Roles other than iron transport?. FEBS Lett 483 (2000) 11-16
20. Richardson D.R., and Morgan E.H. The transferrin homologue, melanotransferrin (p97), is rapidly catabolized by the liver of the rat and does not effectively donate iron to the brain. Biochim Biophys Acta 1690 (2004) 124-133
21. Sekyere E.O., Dunn L.L., Rahmanto Y.S., et al. Role of melanotransferrin in iron metabolism: Studies using targeted gene disruption in vivo. Blood 107 (2006) 2599-2601
22. Dunn L.L., Sekyere E.O., Rahmanto Y.S., et al. The function of melanotransferrin: A role in melanoma cell proliferation and tumorigenesis. Carcinogenesis (2006) May 16 [Epub ahead of print]
23. Napier I., Ponka P., and Richardson D.R. Iron trafficking in the mitochondrion: Novel pathways revealed by disease. Blood 105 (2005) 1867-1874
24. Richardson D.R., Ponka P., and Vyoral D. Distribution of iron in reticulocytes after inhibition of heme synthesis with succinylacetone: Examination of the intermediates involved in iron metabolism. Blood 87 (1996) 3477-3488
25. Ben-Shachar D., Riederer P., and Youdim M.B. Iron-melanin interaction and lipid peroxidation: Implications for Parkinson's disease. J Neurochem 57 (1991) 1609-1614
26. Double K.L., Gerlach M., Schunemann V., et al. Iron-binding characteristics of neuromelanin of the human substantia nigra. Biochem Pharmacol 66 (2003) 489-494
27. Double K.L., Riederer P., and Gerlach M. The significance of neuromelanin in Parkinson's disease. Drug News Dev 12 (1999) 333-340
28. Hentze M.W., and Kuhn L.C. Molecular control of vertebrate iron metabolism: mRNA-based regulatory circuits operated by iron, nitric oxide, and oxidative stress. Proc Natl Acad Sci U S A 93 (1996) 8175-8182
29. Polla B.S. Therapy by taking away: the case of iron. Biochem Pharmacol 57 (1999) 1345-1349
30. Barnham K.J., Masters C.L., and Bush A.I. Neurodegenerative diseases and oxidative stress. Nat Rev Drug Discov 3 (2004) 205-214
31. McCance R., and Widdowson E. The absorption and excretion of Fe following oral and intravenous administration. J Phys 94 (1938) 148-154
32. Young A.B. Huntingtin in health and disease. J Clin Invest 111 (2003) 299-302
33. Ruocco H.H., Lopes-Cendes I., Laurito T.L., et al. Clinical presentation of juvenile Huntington disease. Ar Qneuropsiquiatr 64 (2006) 5-9
34. Wang G.H., Mitsui K., Kotliarova S., et al. Caspase activation during apoptotic cell death induced by expanded polyglutamine in N2a cells. Neuroreport 10 (1999) 2435-2438
35. Gauthier L.R., Charrin B.C., Borrell-Pages M., et al. Huntingtin controls neurotrophic support and survival of neurons by enhancing BDNF vesicular transport along microtubules. Cell 118 (2004) 127-138
36. Ross C.A. Polyglutamine pathogenesis: Emergence of unifying mechanisms for Huntington's disease and related disorders. Neuron 35 (2002) 819-822
37. Lin X., Cummings C.J., and Zoghbi H.Y. Expanding our understanding of polyglutamine diseases through mouse models. Neuron 24 (1999) 499-502
38. Beal M.F., Hyman B.T., and Koroshetz W. Do defects in mitochondrial energy metabolism underlie the pathology of neurodegenerative diseases?. Trends Neurosci 16 (1993) 125-131
39. Browne S.E., Ferrante R.J., and Beal M.F. Oxidative stress in Huntington's disease. Brain Pathol 9 (1999) 147-163
40. Goswami A., Dikshit P., Mishra A., et al. Oxidative stress promotes mutant huntingtin aggregation and mutant huntingtin-dependent cell death by mimicking proteasomal malfunction. Biochem Biophys Res Commun 342 (2006) 184-190
41. Dexter D.T., Carayon A., Javoy-Agid F., et al. Alterations in the levels of iron, ferritin and other trace metals in Parkinson's disease and other neurodegenerative diseases affecting the basal ganglia. Brain 114 (1991) 1953-1975
42. Hilditch-Maguire P., Trettel F., Passani L.A., et al. Huntingtin: An iron-regulated protein essential for normal nuclear and perinuclear organelles. Hum Mol Genet 9 (2000) 2789-2797
43. Bush A.I., and Tanzi R.E. The galvanization of beta-amyloid in Alzheimer's disease. Proc Natl Acad Sci U S A 99 (2002) 7317-7319
44. Honda K., Casadesus G., Petersen R.B., et al. Oxidative stress and redox-active iron in Alzheimer's disease. Ann N Y Acad Sci 1012 (2004) 179-182
45. Honda K., Smith M.A., Zhu X., et al. Ribosomal RNA in Alzheimer disease is oxidized by bound redox-active iron. J Biol Chem 280 (2005) 20978-20986
46. Sipe J.C., Lee P., and Beutler E. Brain iron metabolism and neurodegenerative disorders. Dev Neurosci 24 (2002) 188-196
47. Connor J.R., Snyder B.S., Beard J.L., et al. Regional distribution of iron and iron-regulatory proteins in the brain in aging and Alzheimer's disease. J Neurosci Res 31 (1992) 327-335
48. Smith M.A., Harris P.L., Sayre L.M., et al. Iron accumulation in Alzheimer disease is a source of redox-generated free radicals. Proc Natl Acad Sci U S A 94 (1997) 9866-9888
49. Atwood C.S., Huang X., Moir R.D., et al. Role of free radicals and metal ions in the pathogenesis of Alzheimer's disease. Met Ions Biol Syst 36 (1999) 309-364
50. Bishop G.M., and Robinson S.R. B-Amyloid helps to protect neurons from oxidative stress. Neurobiol Aging 21 (2000) S226
51. Rottkamp C.A., Raina A.K., Zhu X., et al. Redox-active iron mediates amyloid-beta toxicity. Free Radic Biol Med 30 (2001) 447-450
52. Rogers J.T., Randall J.D., Cahill C.M., et al. An iron-responsive element type II in the 5′-untranslated region of the Alzheimer's amyloid precursor protein transcript. J Biol Chem 277 (2002) 45518-45528
53. Levenson C.W. Iron and Parkinson's disease: Chelators to the rescue?. Nutr Rev 61 (2003) 311-313
54. Grunblatt E., Mandel S., Jacob-Hirsch J., et al. Gene expression profiling of parkinsonian substantia nigra pars compacta; alterations in ubiquitin-proteasome, heat shock protein, iron and oxidative stress regulated proteins, cell adhesion/cellular matrix and vesicle trafficking genes. J Neural Transm 111 (2004) 1543-1573
55. Mandel S., Grunblatt E., Riederer P., et al. Neuroprotective strategies in Parkinson's disease: An update on progress. CNS Drugs 17 (2003) 729-762
56. Youdim M.B., Stephenson G., and Ben Shachar D. Ironing iron out in Parkinson's disease and other neurodegenerative diseases with iron chelators: A lesson from 6-hydroxydopamine and iron chelators, desferal and VK-28. Ann N Y Acad Sci 1012 (2004) 306-325
57. Kaur D., Yantiri F., Rajagopalan S., et al. Genetic or pharmacological iron chelation prevents MPTP-induced neurotoxicity in vivo: A novel therapy for Parkinson's disease. Neuron 37 (2003) 899-909
58. Gorell J.M., Ordidge R.J., Brown G.G., et al. Increased iron-related MRI contrast in the substantia nigra in Parkinson's disease. Neurology 45 (1995) 1138-1143
59. Ryvlin P., Broussolle E., Piollet H., et al. Magnetic resonance imaging evidence of decreased putamenal iron content in idiopathic Parkinson's disease. Arch Neurol 52 (1995) 583-588
60. Bartzokis G., Beckson M., Hance D.B., et al. MR evaluation of age-related increase of brain iron in young adults and older normal males. Magn Reson Imaging 15 (1997) 29-35
61. Riederer P., Sofic E., Rausch W.D., et al. Transition metals, ferritin, glutathione, and ascorbic acid in parkinsonian brains. J Neurochem 52 (1989) 515-520
62. Bharath S., Hsu M., Kaur D., et al. Glutathione, iron and Parkinson's disease. Biochem Pharmacol 64 (2002) 1037-1048
63. el-Agnaf O.M., and Irvine G.B. Aggregation and neurotoxicity of alpha-synuclein and related peptides. Biochem Soc Trans 30 (2002) 559-565
64. Faucheux B.A., Martin M.E., Beaumont C., et al. Lack of up-regulation of ferritin is associated with sustained iron regulatory protein-1 binding activity in the substantia nigra of patients with Parkinson's disease. J Neurochem 83 (2002) 320-330
65. Thompson K., Menzies S., Muckenthaler M., et al. Mouse brains deficient in H-ferritin have normal iron concentration but a protein profile of iron deficiency and increased evidence of oxidative stress. J Neurosci Res 71 (2003) 46-63
66. Faucheux B.A., Martin M.E., Beaumont C., et al. Neuromelanin associated redox-active iron is increased in the substantia nigra of patients with Parkinson's disease. J Neurochem 86 (2003) 1142-1148
67. Lopiano L., Chiesa M., Digilio G., et al. Q-band EPR investigations of neuromelanin in control and Parkinson's disease patients. Biochim Biophys Acta 1500 (2000) 306-312
68. Campuzano V., Montermini L., Molto M.D., et al. Friedreich's ataxia: Autosomal recessive disease caused by an intronic GAA triplet repeat expansion. Science 271 (1996) 1423-1427
69. Koutnikova H., Campuzano V., Foury F., et al. Studies of human, mouse and yeast homologues indicate a mitochondrial function for frataxin. Nat Genet 16 (1997) 345-351
70. De Michele G., Perrone F., Filla A., et al. Age of onset, sex, and cardiomyopathy as predictors of disability and survival in Friedreich's disease: A retrospective study on 119 patients. Neurology 47 (1996) 1260-1264
71. Harding A.E. Friedreich's ataxia: A clinical and genetic study of 90 families with an analysis of early diagnostic criteria and intrafamilial clustering of clinical features. Brain 104 (1981) 589-620
72. Durr A., Cossee M., Agid Y., et al. Clinical and genetic abnormalities in patients with Friedreich's ataxia. N Engl J Med 335 (1996) 1169-1175
73. Cossee M., Puccio H., Gansmuller A., et al. Inactivation of the Friedreich ataxia mouse gene leads to early embryonic lethality without iron accumulation. Hum Mol Genet 9 (2000) 1219-1226
74. Bradley J.L., Blake J.C., Chamberlain S., et al. Clinical, biochemical and molecular genetic correlations in Friedreich's ataxia. Hum Mol Genet 9 (2000) 275
75. Alper G., and Narayanan V. Friedreich's ataxia. Pediatr Neurol 28 (2003) 335
76. Lodi R., Rajagopalan B., Bradley J.L., et al. Mitochondrial dysfunction in Friedreich's ataxia: From pathogenesis to treatment perspectives. Free Radic Res 36 (2002) 461-466
77. Van Driest S.L., Gakh O., Ommen S.R., et al. Molecular and functional characterization of a human frataxin mutation found in hypertrophic cardiomyopathy. Mol Genet Metab 85 (2005) 280-285
78. Babcock M., de Silva D., Oaks R., et al. Regulation of mitochondrial iron accumulation by Yfh1p, a putative homolog of frataxin. Science 276 (1997) 1709-1712
79. Campuzano V., Montermini L., Lutz Y., et al. Frataxin is reduced in Friedreich ataxia patients and is associated with mitochondrial membranes. Hum Mol Genet 6 (1997) 1771-1780
80. Foury F., and Cazzalini O. Deletion of the yeast homologue of the human gene associated with Friedreich's ataxia elicits iron accumulation in mitochondria. FEBS Lett 411 (1997) 373-377
81. Radisky D.C., Babcock M.C., and Kaplan J. The yeast frataxin homologue mediates mitochondrial iron efflux. Evidence for a mitochondrial iron cycle. J Biol Chem 274 (1999) 4497-4499
82. Wong A., Yang J., Cavadini P., et al. The Friedreich's ataxia mutation confers cellular sensitivity to oxidant stress which is rescued by chelators of iron and calcium and inhibitors of apoptosis. Hum Mol Genet 8 (1999) 425-430
83. Rotig A., de Lonlay P., Chretien D., et al. Aconitase and mitochondrial iron-sulphur protein deficiency in Friedreich ataxia. Nat Genet 17 (1997) 215-217
84. Lamarche J., Shapcott D., Côté M., et al. Handbook of Cerebellar Diseases (1993), Marcel Dekker, New York, NY 453-458
85. Puccio H., Simon D., Cossee M., et al. Mouse models for Friedreich ataxia exhibit cardiomyopathy, sensory nerve defect and Fe-S enzyme deficiency followed by intramitochondrial iron deposits. Nat Genet 27 (2001) 181-186
86. Park S., Gakh O., Mooney S.M., et al. The ferroxidase activity of yeast frataxin. J Biol Chem 277 (2002) 38589-38595
87. Park S., Gakh O., O'Neill H.A., et al. Yeast frataxin sequentially chaperones and stores iron by coupling protein assembly with iron oxidation. J Biol Chem 278 (2003) 31340-31351
88. O'Neill H.A., Gakh O., Park S., et al. Assembly of human frataxin is a mechanism for detoxifying redox-active iron. Biochemistry 44 (2005) 537-545
89. Eaton J.W., and Qian M. Molecular bases of cellular iron toxicity. Free Radic Biol Med 32 (2002) 833-840
90. Seznec H., Simon D., Monassier L., et al. Idebenone delays the onset of cardiac functional alteration without correction of Fe-S enzymes deficit in a mouse model for Friedreich ataxia. Hum Mol Genet 13 (2004) 1017-1024
91. Seznec H., Simon D., Bouton C., et al. Friedreich ataxia: The oxidative stress paradox. Hum Mol Genet 14 (2005) 463
92. Schulz J.B., Dehmer T., Schols L., et al. Oxidative stress in patients with Friedreich ataxia. Neurology 55 (2000) 1719-1721
93. Bradley J.L., Homayoun S., Hart P.E., et al. Role of oxidative damage in Friedreich's ataxia. Neurochem Res 29 (2004) 561-567
94. Chaston T.B., and Richardson D.R. Iron chelators for the treatment of iron overload disease: Relationship between structure, redox activity, and toxicity. Am J Hematol 73 (2003) 200-210
95. Kalinowski D.S., and Richardson D.R. The evolution of iron chelators for the treatment of iron overload disease and cancer. Pharmacol Rev 57 (2005) 547-583
96. Richardson D.R., Mouralian C., Ponka P., et al. Development of potential iron chelators for the treatment of Friedreich's ataxia: Ligands that mobilize mitochondrial iron. Biochim Biophys Acta 1536 (2001) 133-140
97. Liu Z.D., and Hider R.C. Design of clinically useful iron(III)-selective chelators. Med Res Rev 22 (2002) 26-64
98. Harris D.C., and Aisen P. Facilitation of Fe(II) autoxidation by Fe(3) complexing agents. Biochim Biophys Acta 329 (1973) 156-158
99. Tillbrook G.S., and Hider R.C. Iron chelators for clinical use. In: Sigel A., and Sigel H. (Eds). Metal Irons in Biological Systems vol 35 (1998), Marcel Dekker, New York, NY 691-730
100. Hollander D., Ricketts D., and Boyd C.A.R. Importance of probe molecular geometry in determining intestinal permeability. Can J Gastroenterol 2 (1988) 35A-38A
101. Oldendorf W.H. Lipid solubility and drug penetration of the blood brain barrier. Proc Soc Exp Biol Med 147 (1974) 813-815
102. Maxton D.G., Bjarnason I., Reynolds A.P., et al. Lactulose, 51Cr-labelled ethylenediaminetetra-acetate. L-rhamnose and polyethyleneglycol 400 [corrected] as probe markers for assessment in vivo of human intestinal permeability Clin Sci (Lond) 71 (1986) 71-80
103. Richardson D.R., Wis Vitolo L.M., Hefter G.T., et al. Iron chelators of the pyridoxal isonicotinoyl hydrazone class. Part I. Ionization characteristics of the ligands and their relevance to biological properties. Inorg Chim Acta 170 (1990) 165-170
104. Florence A., and Attwood D. Physicochemical principles of pharmacy (1988), Macmillan, London
105. Cunningham M.J., and Nathan D.G. New developments in iron chelators. Curr Opin Hematol 12 (2005) 129-134
106. Olivieri N.F., and Brittenham G.M. Iron-chelating therapy and the treatment of thalassemia. Blood 89 (1997) 739-761
107. Aouad F., Florence A., Zhang Y., et al. Evaluation of new iron chelators and their therapeutic potential. Inorg Chim Acta 339 (2002) 470-480
108. Wong C.S., Kwok J.C., and Richardson D.R. PCTH: A novel orally active chelator of the aroylhydrazone class that induces iron excretion from mice. Biochim Biophys Acta 1739 (2004) 70-80
109. Ben-Shachar D., Eshel G., Finberg J.P., et al. The iron chelator desferrioxamine (Desferal) retards 6-hydroxydopamine-induced degeneration of nigrostriatal dopamine neurons. J Neurochem 56 (1991) 1441-1444
110. Lan J., and Jiang D.H. Desferrioxamine and vitamin E protect against iron and MPTP-induced neurodegeneration in mice. J Neural Transm 104 (1997) 469
111. Pierre J.L., Baret P., and Serratrice G. Hydroxyquinolines as iron chelators. Curr Med Chem 10 (2003) 1077-1084
112. Martell A., and Smith R. Critical Stability Constants (1977), Plenum Press, New York
113. Jonas S.K., and Riley P.A. The effect of ligands on the uptake of iron by cells in culture. Cell Biochem Funct 9 (1991) 245-253
114. Frederickson C.J., Kasarskis E.J., Ringo D., et al. A quinoline fluorescence method for visualizing and assaying the histochemically reactive zinc (bouton zinc) in the brain. J Neurosci Methods 20 (1987) 91-103
115. Cherny R.A., Atwood C.S., Xilinas M.E., et al. Treatment with a copper-zinc chelator markedly and rapidly inhibits beta-amyloid accumulation in Alzheimer's disease transgenic mice. Neuron 30 (2001) 665-676
116. Zheng H., Youdim M.B., Weiner L.M., et al. Synthesis and evaluation of peptidic metal chelators for neuroprotection in neurodegenerative diseases. J Pept Res 66 (2005) 190-203
117. Bush A.I. Metal complexing agents as therapies for Alzheimer's disease. Neurobiol Aging 23 (2002) 1031-1038
118. Shiraki H. The neuropathology of subacute myelo-optico-neuropathy, "SMON", in the humans: With special reference to the quinoform intoxication. Jpn J Med Sci Biol 28 Suppl (1975) 101-164
119. Yassin M.S., Ekblom J., Xilinas M., et al. Changes in uptake of vitamin B(12) and trace metals in brains of mice treated with clioquinol. J Neurol Sci 173 (2000) 40-44
120. Jenagaratnam L., and McShane R. Clioquinol for the treatment of Alzheimer's Disease. Cochrane Database Syst Rev 1 (2006) CD005380
121. Nguyen T., Hamby A., and Massa S.M. Clioquinol down-regulates mutant huntingtin expression in vitro and mitigates pathology in a Huntington's disease mouse model. Proc Natl Acad Sci U S A 102 (2005) 11840-11845
122. Ritchie C.W., Bush A.I., Mackinnon A., et al. Metal-protein attenuation with iodochlorhydroxyquin (clioquinol) targeting Abeta amyloid deposition and toxicity in Alzheimer disease: A pilot phase 2 clinical trial. Arch Neurol 60 (2003) 1685-1691
123. Atwood C.S., Scarpa R.C., Huang X., et al. Characterization of copper interactions with alzheimer amyloid beta peptides: Identification of an attomolar-affinity copper binding site on amyloid beta1-42. J Neurochem 75 (2000) 1219-1233
124. Ponka P., Borova J., Neuwirt J., et al. Mobilization of iron from reticulocytes. Identification of pyridoxal isonicotinoyl hydrazone as a new iron chelating agent. FEBS Lett 97 (1979) 317-321
125. Hoy T., Humphrys J., Jacobs A., et al. Effective iron chelation following oral administration of an isoniazid-pyridoxal hydrazone. Br J Haematol 43 (1979) 443-449
126. Brittenham G.M. Pyridoxal isonicotinoyl hydrazone: An effective iron-chelator after oral administration. Semin Hematol 27 (1990) 112-116
127. Richardson D.R., Hefter G.T., May P.M., et al. Iron chelators of the pyridoxal isonicotinoyl hydrazone class. III. Formation constants with calcium(II), magnesium(II) and zinc(II). Biol Met 2 (1989) 161-167
128. Richardson D.R., Vitolo L., Hefter G.T., et al. Iron chelators of the pyridoxal isonicotinoyl hydrazone class. Part I. Ionisation characteristics of the ligand and their relevance to biological properties. Inorg Chim Acta 170 (1990) 165-170
129. Ponka P., Richardson D.R., Edward J.T., et al. Iron chelators of the pyridoxal isonicotinoyl hydrazone class. Relationship of the lipophilicity of the apochelator to its ability to mobilise iron from reticulocytes in vitro. Can J Physiol Pharmacol 72 (1994) 659-666
130. Johnson D.K., Pippard M.J., Murphy T.B., et al. An in vivo evaluation of iron-chelating drugs derived from pyridoxal and its analogs. J Pharmacol Exp Ther 221 (1982) 399-403
131. Richardson D.R., Tran E.H., and Ponka P. The potential of iron chelators of the pyridoxal isonicotinoyl hydrazone class as effective antiproliferative agents. Blood 86 (1995) 4295-4306
132. Becker E., and Richardson D.R. Development of novel aroylhydrazone ligands for iron chelation therapy: 2-pyridylcarboxaldehyde isonicotinoyl hydrazone analogs. J Lab Clin Med 134 (1999) 510-521
133. Richardson D.R., and Ponka P. Pyridoxal isonicotinoyl hydrazone and its analogs: potential orally effective iron-chelating agents for the treatment of iron overload disease. J Lab Clin Med 131 (1998) 306-315
134. Richardson D.R., Becker E., and Bernhardt P.V. The biologically active iron chelators 2- pyridylcarboxaldehyde isonicotinoyl hydrazone, 2-pyridylcarboxaldehyde benzoyl hydrazone and 2-furfural isonicotinoyl hydrazone. Acta Crystallographica Section C C55 (1999) 2102-2105
135. Bernhardt P.V., Chin P., and Richardson D.R. Unprecedented oxidation of a biologically active aroylhydrazone chelator catalysed by iron(III): Serendipitous identification of diacylhydrazine ligands with high iron chelation efficacy. J Biol Inorg Chem 6 (2001) 801-809
136. Richardson D.R. Friedreich's ataxia: Iron chelators that target the mitochondrion as a therapeutic strategy?. Expert Opin Investig Drugs 12 (2003) 235-245
137. Klausner R.D., and Dancis A. A genetic approach to elucidating eukaryotic iron metabolism. FEBS Lett 355 (1994) 109-113
138. Hassett R., Dix D.R., Eide D.J., et al. The Fe(II) permease Fet4p functions as a low affinity copper transporter and supports normal copper trafficking in Saccharomyces cerevisiae. Biochem J 351 (2000) 477-484